PRESS INFORMATION BUREAU पत्र सचना कार्यालय GOVERNMENT OF INDIA भारत सरकार

Asian Age, Delhi Thursday 17th January 2013, Page: 17 Width: 12.43 cms, Height: 11.77 cms, a4, Ref: pmin.2013-01-17.43.164

## India to become hub of biosimilars in next 5 years

API exports soon'

Centre is likely to come

up with draft guidelines

on the certification of

exports of active phar-

the EU within a month,

says Pharmaexcil.

maceutical ingredients to

and are used for the same

therapeutic indication, as

The market for biosimi-lars globally stands at \$580 million and is expected to grow to \$10 billion by 2015,

said Shakthi M. Nagappan,

Mr Nagap-pan said that

vaccines and other prod-

ucts) is anticipated to lose

its patent protection by

biopharmaceuticals (consisting of biosimilars,

the innovator product.

CEO, BioAsia.

AGE CORRESPONDENT HYDERABAD, JAN. 16

Despite having a strong presence in the generic drugs sector across the globe, India is yet to grow as a hub of biosimilars where China and South Korea are in the lead.

However, India won't find it difficult to catch up with China, said Dr P.V. Appaji, director-general, Pharm-aexcil, adding that it is expected to grab 20-25 per cent share in the global biosimilars market in the next five years.

Currently, India accounts for 2-3 per cent of the global biolsimilars market. "India should be at third

or fourth position in the biogenerics market in the next five years," he said.

**Biosimilars** are generic versions of biological medicines that depend on the 2015. same mechanism of action, and Meanwhile, the piophar-

the

'Draft guidelines on maceuticals market stands at \$100 billion.

According to Mr Appaji, 70-80 per cent of therapy will be replaced by biosimilars, that will outperform chemical drugs, by 2020. At present, the chemical drugs market is at \$700 billion globally.

Even venture capitalists are open to invest in research and development of biolsimilars, Mr Nagappan explained.

This has also given rise to pharma companies looking for tie-ups to develop biosimilar drugs. In India over 100 companies including players like Dr. Reddy's, Intas and Reliance are involved in R&D.

The focus on biosimilars is expected to draw many stakeholders from across the world to BioAsia 2013, a global summit, that will be held in Hyderabad from January 28-30

Industry